A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE
Latest Information Update: 05 Jun 2020
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; DTaP vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Jul 2018 Planned End Date changed from 28 May 2019 to 24 May 2019.
- 11 Jul 2018 Planned primary completion date changed from 28 May 2019 to 24 May 2019.